PMS-LIDOCAINE VISCOUS 2% LIQUID
País: Canadà
Idioma: anglès
Font: Health Canada
Fitxa tècnica
(SPC)
07-04-2016
Alguns documents d’aquest producte actualment no estan disponibles, podeu enviar una sol·licitud al nostre servei d’atenció al client i us ho notificarem tan bon punt puguem obtenir-los.
Enviar sol.licitud.
Enviar sol.licitud.
ingredients actius:
LIDOCAINE HYDROCHLORIDE
Disponible des:
PHARMASCIENCE INC
Codi ATC:
N01BB02
Designació comuna internacional (DCI):
LIDOCAINE
Dosis:
2%
formulario farmacéutico:
LIQUID
Composición:
LIDOCAINE HYDROCHLORIDE 2%
Vía de administración:
DENTAL
Unidades en paquete:
100,50 ML
tipo de receta:
OTC
Área terapéutica:
LOCAL ANESTHETICS
Resumen del producto:
Active ingredient group (AIG) number: 0101280001; AHFS:
Estat d'Autorització:
MARKETED
Data d'autorització:
1990-12-31
Fitxa tècnica
PRESCRIBING INFORMATION
PMS-LIDOCAINE VISCOUS 2%
Lidocaine Hydrochloride Oral Topical Solution, USP
20 mg/mL
Oral Topical Anesthetic
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montreal, Quebec
H4P 2T4
www.pharmascience.com
Date of Revision:
April 6, 2016
Submission Control No: 193450
_ _
_ _
_Prescribing Information ~ pms-LIDOCAINE VISCOUS 2% _
_Page 2 of 21 _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................8
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................11
OVERDOSAGE
................................................................................................................13
ACTION AND CLINICAL PHARMACOLOGY
............................................................14
STORAGE AND STABILITY
..........................................................................................16
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................16
REFERENCES
..................................................................................................................17
PART III: CONSUMER
INFORMATION...............................................................................18
_ _
_ _
_Prescribing Information ~ pms-LIDOCAINE VISCOUS 2% _
_Page 3 of 21 _
_ _
PMS-LIDOCAINE VISCOUS
Llegiu el document complet
